Biotech Stocks At 52-Week Highs - UFPT +25%, INFU +33%, SOPH +20% On Q2 Reports, REPL, PBLS
Biotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.
How this was made
The 30-second read
Why it matters
For UFPT, INFU, and SOPH, the immediate catalysts are reported quarterly financials and full-year guidance. For REPL, the catalyst is FDA BLA progress and advisory committee interpretation, with a pending Class 1 response timeline mentioned. For PBLS, the catalyst is more narrative around its lead program and FDA designations rather than a clearly new datapoint in the text.
Market read
Traders can use the reported Q2 figures and explicit guidance ranges (UFPT, INFU, SOPH) and the FDA BLA milestone plus pending response timing (REPL) to frame near-term momentum and event-risk positioning.
What to watch
The article lacks consensus estimates and prior guidance comparisons, so traders may be over-weighting the magnitude of the reported numbers versus expectations.
Background
A multi-name biotech roundup highlights stocks hitting 52-week highs on Aug 4, 2026, citing Q2 results, guidance, and FDA-related milestones.
Ticker impact
UFPT surged over 25% to a 52-week high after reporting Q2 net income of $20.9M and sales of $174M.
Likely supports continued momentum trading near-term, but follow-through depends on whether results beat expectations.
The article provides concrete Q2 financial figures and ties the move directly to the report, but it lacks consensus/estimate context.
INFU jumped over 33% to a 52-week high after Q2 revenue of $36.9M and full-year pro-forma net revenue growth guidance of 6% to 8%.
Near-term upside bias for momentum traders, with sensitivity to whether the 6% to 8% growth range is viewed as conservative or credible.
The article includes both the Q2 datapoint and explicit full-year growth guidance, but no estimate comparison is provided.
REPL rose to a 52-week high after receiving a favorable FDA opinion on its BLA and noting Phase 3 IGNYTE results were viewed as clinically meaningful.
Potential volatility into the pending FDA Class 1 response timeline, with upside skew if the response is favorable.
The text flags a favorable opinion and an expected Class 1 response date that has not been reported, but it does not confirm the final decision.
SOPH hit a 52-week high after Q2 revenue of $23.3M (up 27%) and full-year 2026 revenue guidance of $94M to $96M.
Supports continued bullish momentum, especially if investors focus on U.S. growth and DDM analysis volume.
The article provides specific growth rates and guidance, but lacks valuation context and whether guidance changed versus prior expectations.
PBLS reached a 52-week high after IPO-related trading and describing its lead Helicon peptide Zolucatetide Phase 1/2 progress plus FDA Fast Track and Orphan Drug designations.
Likely remains headline-driven and volatile, with price sensitive to any new Phase 1/2 readouts.
The article does not provide new trial results or a fresh regulatory action on the day, so the catalyst quality is weaker than for the earnings/guidance names.
Market effects
Broad biotech risk appetite appears to be supported by company-specific earnings strength (UFPT, INFU, SOPH) and regulatory/clinical catalysts (REPL, PBLS).
Primarily US-listed biotech momentum, with no explicit cross-region macro linkage described.
Limited global spillover indicated; the article is company-specific rather than a global biotech policy or trial-wide development.
Counterpoint
52-week-high breakouts can reverse if the moves outpace fundamentals, especially for clinical-stage names where the next FDA decision or trial readout is the real driver.
Key entities
- public_companyUFP Technologies Inc.
Contract development and manufacturing firm; Q2 earnings and sales growth cited as the driver of a >25% jump to a 52-week high.
- public_companyInfuSystem Holdings Inc.
Healthcare services provider; Q2 revenue and 2026 pro-forma net revenue growth guidance cited alongside a >33% surge.
- public_companyReplimune Group Inc.
Clinical-stage oncolytic immunotherapy developer; favorable FDA BLA opinion and advisory committee view cited.
- public_companySOPHiA Genetics SA
AI-driven precision medicine software; Q2 growth and 2026 revenue guidance cited as the driver of a >20% move.
- public_companyParabilis Medicines Inc.
Clinical-stage helical peptide therapeutics company; Zolucatetide program and FDA designations cited.
